超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

加拿大Medicago ?
公司是基于植物技術的組合式人體疫苗研發先鋒。面對流行性傳染病和季節性傳染病疫苗供求的挑戰，公司成功研制出自有知識產權的瞬變表達系統，該系統使用來自于非轉基因植物葉片中的抗原。 公司位于加拿大魁北克市，擁有1300平方米的領軍設施，包括高科技溫室及下游研發設備。 公司提供多種優于傳統蛋基技術及細胞培植技術的強勢：速度（3個月內即產出數百萬劑），單支劑量的生產成本，以及極低的投資。 目前的產品包括疫苗抗體組合：HA和 NA流感抗體，以及大面積傳染性疾病疫苗。

?Medicago is developing highly effective and affordable vaccines based on two proprietary technologies: its plant-based Proficia? manufacturing technology and its Virus-Like Particles (VLPs). Proficia? is a robust vaccine and antibody production system based on protein expression in plant leaves. This technology has the potential to offer speed and cost advantages over traditional egg-based and cell production systems. It can deliver a vaccine for testing in less than a month after the identification and reception of genetic sequences from a pandemic strain. Medicago’s VLPs resemble a virus, allowing them to be recognized readily by the immune system however they lack the core genetic material, making them non-infectious and unable to replicate. The Company is currently using tobacco leaves to produce pandemic and seasonal influenza VLP vaccines.
?